Creation of a chemotherapy-induced nausea/vomiting dashboard to improve outcomes for pediatric cancer patients.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 05 07 2019
accepted: 22 07 2020
pubmed: 1 8 2020
medline: 9 3 2021
entrez: 1 8 2020
Statut: ppublish

Résumé

Two of the most common acute side effects of chemotherapy are nausea and vomiting. Nausea and vomiting impact quality of life, nutritional status, and ability to tolerate further chemotherapy. Parents of pediatric oncology patients rank nausea as one of the most bothersome treatment-related symptoms. Utilizing Quality Improvement methodology, we developed a dashboard interface to facilitate extraction of data from the electronic medical record (EMR), which is presented via a visual display that summarizes the type of chemotherapy and antiemetic medications, use of as needed medications, and number of episodes of emesis. This dashboard interface allows for rapid and efficient identification of patients whose antiemetic regimen is mismatched for the emetogenicity of ordered chemotherapy, thus providing a timely opportunity to modify the antiemetic regimen based on published guidelines before administration of chemotherapy drugs. It also allows measurement of the effectiveness of the antiemetic regimen in terms of the number of break through emesis and the need for as needed medications. A novel CINV dashboard was created, which visually conveys complex information about antiemetics, chemotherapy emetogenicity, as needed medications, and breakthrough vomiting for inpatient pediatric oncology patients.

Identifiants

pubmed: 32734390
doi: 10.1007/s00520-020-05652-1
pii: 10.1007/s00520-020-05652-1
doi:

Substances chimiques

Antiemetics 0
Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1549-1555

Références

National Cancer Institute: Surveillance, epidemiology, and end results Program, SEER Cancer Review Statistics. (1975-2015). https://seer.cancer.gov/csr/1975_2015/browse_csr.php?sectionSEL=28&pageSEL=sect_28_table.08 . Accessed November 20 2019
Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065–2071. https://doi.org/10.1016/j.bbmt.2018.06.005
doi: 10.1016/j.bbmt.2018.06.005 pubmed: 29906570
Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY (2013) Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J 43(1):73–76. https://doi.org/10.1111/j.1445-5994.2011.02637.x
doi: 10.1111/j.1445-5994.2011.02637.x pubmed: 22141732
Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, O'Shaughnessy E, Sung L, Pediatric Oncology Group of O (2013) Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 60(7):1073–1082. https://doi.org/10.1002/pbc.24508
doi: 10.1002/pbc.24508 pubmed: 23512831
Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25(7):1328–1333. https://doi.org/10.1093/annonc/mdu101
doi: 10.1093/annonc/mdu101 pubmed: 24603643 pmcid: 4071754
Affronti ML, Schneider SM, Herndon JE, Schlundt S, Friedman HS (2014) Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer 22(7):1897–1905. https://doi.org/10.1007/s00520-014-2136-0
doi: 10.1007/s00520-014-2136-0 pubmed: 24570103 pmcid: 4509487
Dupuis LL, Milne-Wren C, Cassidy M, Barrera M, Portwine C, Johnston DL, Silva MP, Sibbald C, Leaker M, Routh S, Sung L (2010) Symptom assessment in children receiving cancer therapy: the parents' perspective. Support Care Cancer 18(3):281–299. https://doi.org/10.1007/s00520-009-0651-1
doi: 10.1007/s00520-009-0651-1 pubmed: 19513763
McKinnon K, Jupp J, Ghosh S, Digout C, Eason S, Romanick M (2018) Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. Pediatr Blood Cancer:e27488. https://doi.org/10.1002/pbc.27488
Polito S, MacDonald T, Romanick M, Jupp J, Wiernikowski J, Vennettilli A, Khanna M, Patel P, Ning W, Sung L, Dupuis LL (2018) Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: a multicenter, retrospective review. Pediatr Blood Cancer 65(12):e27374. https://doi.org/10.1002/pbc.27374
doi: 10.1002/pbc.27374 pubmed: 30051617
Medicine IIo (2011) Clinical practice guidelines we can trust: committee on standards for developing trustworthy clinical practice guidelines. The National Academies Press, Washington DC
Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L (2006) Development and validation of the pediatric nausea assessment tool for use in children receiving antineoplastic agents. Pharmacotherapy 26(9):1221–1231. https://doi.org/10.1592/phco.26.9.1221
doi: 10.1592/phco.26.9.1221 pubmed: 16945043
Dupuis LL, Sung L, Molassiotis A, Orsey AD, Tissing W, van de Wetering M (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25(1):323–331. https://doi.org/10.1007/s00520-016-3384-y
doi: 10.1007/s00520-016-3384-y pubmed: 27565788
Dupuis LL, Boodhan S, Sung L, Portwine C, Hain R, McCarthy P, Holdsworth M, Ontario POGo (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57(2):191–198. https://doi.org/10.1002/pbc.23114
doi: 10.1002/pbc.23114 pubmed: 21465637
Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, Hesketh PJ (2017) 2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer 25(1):271–275. https://doi.org/10.1007/s00520-016-3332-x
doi: 10.1007/s00520-016-3332-x pubmed: 27501965
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, investigators P (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992. https://doi.org/10.1093/annonc/mds021
doi: 10.1093/annonc/mds021 pubmed: 22396444
Dupuis LL, Roscoe JA, Olver I, Aapro M, Molassiotis A (2017) 2016 updated MASCC/ESMO consensus recommendations: anticipatory nausea and vomiting in children and adults receiving chemotherapy. Support Care Cancer 25(1):317–321. https://doi.org/10.1007/s00520-016-3330-z
doi: 10.1007/s00520-016-3330-z pubmed: 27510314
Carroll C, Clinton F, Smith A, Fox A, Capra M, Pears J, Owens C (2018) Revised antiemetics guidelines and the impact on nutritional status during induction chemotherapy in children with high-risk neuroblastoma. Pediatr Blood Cancer 65(12):e27386. https://doi.org/10.1002/pbc.27386
doi: 10.1002/pbc.27386 pubmed: 30230225
Jordan K, Gralla R, Jahn F, Molassiotis A (2014) International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 722:197–202. https://doi.org/10.1016/j.ejphar.2013.09.073
doi: 10.1016/j.ejphar.2013.09.073 pubmed: 24157984
Patel P, Robinson PD, Orsey A, Freedman JL, Langevin AM, Woods D, Sung L, Dupuis LL (2016) Chemotherapy-induced nausea and vomiting prophylaxis: practice within the Children's oncology group. Pediatr Blood Cancer 63(5):887–892. https://doi.org/10.1002/pbc.25915
doi: 10.1002/pbc.25915 pubmed: 26864262 pmcid: 5524586
Weggelaar-Jansen AMJW, Broekharst DSE, de Bruijne M (2018) Developing a hospital-wide quality and safety dashboard: a qualitative research study. BMJ Qual Saf 27:1000–1007. https://doi.org/10.1136/bmjqs-2018-007784
doi: 10.1136/bmjqs-2018-007784 pubmed: 29950323 pmcid: 6288703
Martinez DA, Kane EM, Jalalpour M, Scheulen J, Rupani H, Toteja R, Barbara C, Bush B, Levin SR (2018) An electronic dashboard to monitor patient flow at the Johns Hopkins Hospital: communication of key performance indicators using the Donabedian model. J Med Syst 42(8):133. https://doi.org/10.1007/s10916-018-0988-4
doi: 10.1007/s10916-018-0988-4 pubmed: 29915933
Battjes R, Jones L, Groves C, Fakih M (2017) An innovative approach to evaluate hospital and system improvements in infection prevention: development of a dynamic bacteremia dashboard. Am J Infect Control 45(6):S46
doi: 10.1016/j.ajic.2017.04.070
Lee K, Jung SY, Hwang H, Yoo S, Baek HY, Baek RM, Kim S (2017) A novel concept for integrating and delivering health information using a comprehensive digital dashboard: an analysis of healthcare professionals' intention to adopt a new system and the trend of its real usage. Int J Med Inform 97:98–108. https://doi.org/10.1016/j.ijmedinf.2016.10.001
doi: 10.1016/j.ijmedinf.2016.10.001 pubmed: 27919400
Shaw SJ, Jacobs B, Stockwell DC, Futterman C, Spaeder MC (2015) Effect of a real-time pediatric ICU safety bundle dashboard on quality improvement measures. Jt Comm J Qual Patient Saf 41(9):414–420
pubmed: 26289236
Hagland M (2010) First place. Children's Hospital of Pittsburgh. Improving patient care through data availability in the ICU. Healthc inform 27(3):20–21 23, 26 passim
pubmed: 20931936
Badgeley MA, Shameer K, Glicksberg BS, Tomlinson MS, Levin MA, McCormick PJ, Kasarskis A, Reich DL, Dudley JT (2016) EHDViz: clinical dashboard development using open-source technologies. BMJ Open 6(3):e010579. https://doi.org/10.1136/bmjopen-2015-010579
doi: 10.1136/bmjopen-2015-010579 pubmed: 27013597 pmcid: 4809078
Shailam R, Botwin A, Stout M, Gee MS (2018) Real-time electronic dashboard technology and its use to improve pediatric radiology workflow. Curr Probl Diagn Radiol 47(1):3–5. https://doi.org/10.1067/j.cpradiol.2017.03.002
doi: 10.1067/j.cpradiol.2017.03.002 pubmed: 28533102
Fox LA, Walsh KE, Schainker EG (2016) The creation of a pediatric hospital medicine dashboard: performance assessment for improvement. Hosp Pediatr 6(7):412–419. https://doi.org/10.1542/hpeds.2015-0222
doi: 10.1542/hpeds.2015-0222 pubmed: 27260565
Itri JN, Bakow E, Probyn L, Kadom N, Duong PT, Gettle LM, Mendiratta-Lala M, Scali EP, Winokur RS, Zygmont ME, Kung JW, Rosenkrantz AB (2017) The science of quality improvement. Acad Radiol 24(3):253–262. https://doi.org/10.1016/j.acra.2016.05.010
doi: 10.1016/j.acra.2016.05.010 pubmed: 28193375
Portela MC, Pronovost PJ, Woodcock T, Carter P, Dixon-Woods M (2015) How to study improvement interventions: a brief overview of possible study types. BMJ Qual Saf 24(5):325–336. https://doi.org/10.1136/bmjqs-2014-003620
doi: 10.1136/bmjqs-2014-003620 pubmed: 25810415 pmcid: 4413733
Green LW, Ottoson JM, García C, Hiatt RA (2009) Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health 30:151–174. https://doi.org/10.1146/annurev.publhealth.031308.100049
doi: 10.1146/annurev.publhealth.031308.100049 pubmed: 19705558
Bresnick J (2018) EHR, Lab Data Support Pediatric AKI Analytics Dashboard. https://healthitanalytics.com/news/ehr-lab-data-support-pediatric-aki-analytics-dashboard . Accessed 20 July 2020
Flank J, Nadeem K, Moledina S, Khanna M, Schindera C, Punnett A, Dupuis LL (2017) Nausea and vomiting in children and adolescents receiving intrathecal methotrexate: a prospective, observational study. Pediatr Blood Cancer 64(10). https://doi.org/10.1002/pbc.26603

Auteurs

Alexandra M Walsh (AM)

Center for Cancer and Blood Disorders, Phoenix Children's Hospital, 1919 E. Thomas Road, Phoenix, AZ, 85021, USA. awalsh@phoenixchildrens.com.

Jennifer Hess (J)

Center for Cancer and Blood Disorders, Phoenix Children's Hospital, 1919 E. Thomas Road, Phoenix, AZ, 85021, USA.

Melissa Rees (M)

Department of Pharmacy, Phoenix Children's Hospital, 1919 E. Thomas Road, Phoenix, AZ, 85021, USA.

Cynthia Wetmore (C)

Center for Cancer and Blood Disorders, Phoenix Children's Hospital, 1919 E. Thomas Road, Phoenix, AZ, 85021, USA.

Vinay Vadiya (V)

Information Technology, Phoenix Children's Hospital, 1919 E. Thomas Road, Phoenix, AZ, 85021, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH